Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer
A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation With Concurrent 5-Fluorouracil and Mitomycin-C for Stage I-III Carcinoma of the Anal Canal
Sponsor: National Cancer Institute (NCI)
Terminated
Slow, insufficient accrual and failure to meet endpoints.
Other terminated trials from National Cancer Institute (NCI)
Other Anal Cancer trials with similar outcome
A PHASE1 clinical study on Anal Cancer, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 10 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Mar 2022 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2022 — Mar 2022 [monthly]
Terminated PHASE1
-
Dec 2021 — Jan 2022 [monthly]
Terminated PHASE1
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Aug 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .